Autor/a

Roncero, Carlos

Ros-Cucurull, Elena

Palma-Álvarez, Raúl Felipe

Abad, Alfonso Carlos

Fadeuilhe, Christian

Casas Brugué, Miquel

Grau-López, Lara

Universitat Autònoma de Barcelona

Fecha de publicación

2017

Resumen

Episodes of agitation are frequent in intoxicated patients who have a substance use disorder, a psychiatric disorder or both (dual diagnosis). For managing the agitation, it is necessary to act promptly in a safe environment and addressing any underlying etiology. Inhaled loxapine improves symptoms of agitation in adults with psychiatric disorders (eg, schizophrenia) within 10 minutes of administration. Recently, some reports have documented the usefulness of loxapine in dual diagnoses patients with agitation. However, the efficacy of loxapine in intoxicated patients has not been deeply addressed. This report describes a case series of 12 patients (with addiction or dual disorder) who received inhaled loxapine for symptoms of psychomotor agitation during intoxication with different substances (eg, alcohol, cannabis, or cocaine) at 1 center in Spain. Data from 12 patients were reviewed, 5 patients were attended at the emergency room, 4 at the addiction and dual diagnosis unit, and 3 were treated during hospitalization for detoxification. All patients were under effects of substances. They had substance use disorder (including cannabis, cocaine, alcohol, hypnotics, and hallucinogens), and almost all (90%) presented 1 or more psychiatric disorders. One dose of inhaled loxapine was effective in 9 patients (75%), and in 3 patients, a second dose was required. Only mild dizziness was reported in 1 patient after the second dose. The acute agitation was effectively and quickly managed with inhaled loxapine in all intoxicated patients and enabled the appropriate clinical evaluation of the agitated state and the patient's management.

Tipo de documento

Article

Lengua

Inglés

Materias y palabras clave

Agitation; Inhaled loxapine; Emergency; Substance use disorders; Mental disorders

Publicado por

 

Documentos relacionados

Clinical Neuropharmacology ; Vol. 40 (october 2017), p. 281-285

Derechos

open access

Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.

https://creativecommons.org/licenses/by-nc-nd/4.0/

Este ítem aparece en la(s) siguiente(s) colección(ones)